Acne and Isotretinoin

Deep Dive

In Western clinical practice, isotretinoin is positioned as the definitive monotherapy for severe, scarring, or treatment‑resistant acne because... In Western clinical practice, isotretinoin is positioned as the definitive monotherapy for severe, scarring, or treatment‑resistant acne because it addresses every major pathogenic pathway. By activating nuclear retinoid receptors, it shrinks sebaceous glands and reduces sebum, normalizes desquamation to prevent comedones, decreases Cutibacterium acnes, and exerts anti‑inflammatory effects. Candidates typically include those with nodulocystic disease, frequent relapses despite optimized topical retinoids plus benzoyl peroxide and adequate systemic antibiotics, or significant scarring and psychosocial distress. Treatment is given daily in a weight‑based fashion over several months, aiming for a total cumulative exposure that correlates with longer remissions. Patients often notice improvement within 4–8 weeks; an early flare can occur and is managed supportively. After a single course, many achieve long‑term clearance, though a subset relapse and may need maintenance topicals or a repeat course. Safety governs prescribing. The most common adverse effects are mucocutaneous: cheilitis, xerosis, epistaxis, and dry eyes. Laboratory changes—particularly triglyceride elevations and mild transaminase increases—are usually reversible. Because isotretinoin is teratogenic, those who can become pregnant must adhere to risk‑management programs such as iPLEDGE in the U.S., with confirmed contraception and regular pregnancy testing. Although meta‑analyses have not shown an increased overall risk of depression or suicide, clinicians screen and monitor mood, recognizing acne itself can affect mental health. Concomitant tetracyclines are avoided due to intracranial hypertension risk; excessive vitamin A intake is contraindicated. Baseline history, lipids, and liver enzymes are checked, with repeat testing early in treatment and as indicated thereafter, tailored to individual risk. Adjunctive measures help patients succeed: barrier‑repair moisturizers and lip care, broad‑spectrum sunscreen, gentle cleansers, and simple, non‑comedogenic routines. For those with androgen‑driven features, concurrent contraception addresses teratogenicity and can improve acne; antiandrogen strategies may reduce relapse. When isotretinoin is unsuitable, options include topical combinations, oral antibiotics (limited duration), hormonal therapy, and device‑based treatments such as photodynamic therapy. The clinical goal is durable remission with a safety plan that is transparent and collaborative.